Self-funded employer plans (where the employer pays claims directly and contracts with an insurer for administration) have wide latitude to include or exclude obesity medications
As a result, they are increasingly used in patients with both diabetes and cardiovascular disease
He hoped to sell higher volumes of obesity and diabetes drugs over the coming years, saying: We are seeing a volume response to lower prices. He pointed to Novos agreement with the Trump administration to cut prices heavily, from more than $1,000 a month (730) to an average price of $350 (255), and the patent expiry of semaglutide, the main ingredient of its obesity and diabetes drugs, in several countries including India
To view a copy of this licence, visit About this article Cite this article Lewis, J.E., Montaner, M., Nuzzaci, D
Im going to stick with 2.0mg per day The mice can have all the fun with this one 2 Likes LukeMV April 15, 2026, 6:48pm #11 The burn/red marks from the injections on occasion kind of suck